The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. Watch this webinar to learn about how this test, especially with its latest active surveillance insights, could benefit you, your patients and your practice.
The ArteraAI Prostate Test was recently included as the first and only prognostic and predictive AI test in the NCCN Guidelines® for localized prostate cancer. Unlike genomic tests, the ArteraAI Prostate Test is a digital pathology test with a turnaround time of 24-36 hours upon receipt of the biopsy slide.
Dr. Zachary Horne (Allegheny Health) and Dr. Timothy Kegelman (ChristianaCare) joins Artera’s Dr. Trevor Royce in reviewing the evidence behind the test, as well as discussing a few patient cases of how the test results impacted treatment decisions.
Fill out the form to view the recording…
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. Watch this webinar to learn about how this test, especially with its latest active surveillance insights, could benefit you, your patients and your practice.
The ArteraAI Prostate Test was recently included as the first and only prognostic and predictive AI test in the NCCN Guidelines® for localized prostate cancer. Unlike genomic tests, the ArteraAI Prostate Test is a digital pathology test with a turnaround time of 24-36 hours upon receipt of the biopsy slide.
Dr. Zachary Horne (Allegheny Health) and Dr. Timothy Kegelman (ChristianaCare) joins Artera’s Dr. Trevor Royce in reviewing the evidence behind the test, as well as discussing a few patient cases of how the test results impacted treatment decisions.
